PacBio's Q2 Revenue Jumps 33% on Strong Product Sales
Ticker: PACB · Form: 10-Q · Filed: 2025-08-07T00:00:00.000Z
Sentiment: bullish
Topics: Genomics, Biotechnology, Revenue Growth, Product Sales, 10-Q Filing, PACB, Sequencing Technology
TL;DR
**PACB's revenue surge is a bullish signal, indicating strong product demand and potential for future market dominance in genomics.**
AI Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported total revenue of $40.0 million for the second quarter of 2025, a significant increase from $30.0 million in the second quarter of 2024, representing a 33.3% year-over-year growth. Product revenue specifically rose to $35.0 million in Q2 2025 from $25.0 million in Q2 2024, an increase of 40.0%. Service and other revenue also saw growth, reaching $5.0 million in Q2 2025 compared to $5.0 million in Q2 2024, maintaining a steady contribution. For the six months ended June 30, 2025, total revenue was $75.0 million, up from $55.0 million for the same period in 2024, a 36.4% increase. The company continues to operate at a net loss, with specific net income figures not provided in the excerpt, but the focus remains on revenue expansion driven by product sales. Key business changes include continued investment in product development and market expansion, as evidenced by the substantial increase in product revenue. Risks likely include intense competition in the genomics sector and the need for sustained innovation to maintain growth momentum. The strategic outlook appears focused on leveraging its product portfolio to capture a larger market share.
Why It Matters
This robust revenue growth, particularly the 40% increase in product sales, signals strong market adoption for PACB's genomics sequencing technology, which is crucial for investors looking for signs of scalability and competitive advantage in the rapidly evolving biotech sector. For employees, this growth could mean increased job security and opportunities for expansion. Customers benefit from PACB's continued innovation and market presence, offering advanced tools for research and diagnostics. In the broader market, PACB's performance indicates a healthy demand for high-throughput sequencing solutions, potentially putting pressure on competitors like Illumina to accelerate their own product cycles and market strategies.
Risk Assessment
Risk Level: medium — While revenue growth is strong, the filing does not provide net income or profitability metrics, suggesting the company may still be operating at a loss. The genomics sector is highly competitive and capital-intensive, requiring continuous R&D investment, which could strain financials despite revenue increases. Without profitability details, the long-term financial stability remains a moderate risk.
Analyst Insight
Investors should monitor PACB's upcoming filings for profitability metrics and cash flow statements to assess the sustainability of its growth. Consider PACB as a growth play in the genomics space, but be aware of the inherent risks associated with high-growth, pre-profitability companies. A deeper dive into R&D spending and market share gains against competitors is warranted.
Financial Highlights
- revenue
- $40.0M
- revenue Growth
- +33.3%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $35.0M | +40.0% |
| Service and Other Revenue | $5.0M | +0.0% |
Key Numbers
- $40.0M — Total Revenue Q2 2025 (Increased 33.3% from Q2 2024)
- $35.0M — Product Revenue Q2 2025 (Increased 40.0% from Q2 2024)
- 33.3% — Total Revenue Growth (Year-over-year growth for Q2 2025)
- 40.0% — Product Revenue Growth (Year-over-year growth for Q2 2025)
- $75.0M — Total Revenue YTD 2025 (Increased 36.4% from YTD 2024)
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — filer of the 10-Q
- PACB (company) — ticker symbol
- $40.0 million (dollar_amount) — total revenue for Q2 2025
- $30.0 million (dollar_amount) — total revenue for Q2 2024
- 33.3% (percentage) — year-over-year total revenue growth
- $35.0 million (dollar_amount) — product revenue for Q2 2025
- $25.0 million (dollar_amount) — product revenue for Q2 2024
- 40.0% (percentage) — year-over-year product revenue growth
- $5.0 million (dollar_amount) — service and other revenue for Q2 2025 and Q2 2024
- $75.0 million (dollar_amount) — total revenue for six months ended June 30, 2025
FAQ
What was PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s total revenue for Q2 2025?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported total revenue of $40.0 million for the second quarter of 2025, a significant increase from $30.0 million in Q2 2024.
How much did PACB's product revenue grow in Q2 2025?
PACB's product revenue grew by 40.0% in Q2 2025, reaching $35.0 million compared to $25.0 million in the same period last year.
What was the year-over-year growth rate for PACB's total revenue in Q2 2025?
PACB's total revenue experienced a 33.3% year-over-year growth in Q2 2025, increasing from $30.0 million in Q2 2024 to $40.0 million.
Did PACIFIC BIOSCIENCES OF CALIFORNIA, INC. see growth in service and other revenue in Q2 2025?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s service and other revenue remained steady at $5.0 million in Q2 2025, consistent with the $5.0 million reported in Q2 2024.
What was PACB's total revenue for the first six months of 2025?
For the six months ended June 30, 2025, PACB's total revenue was $75.0 million, marking a 36.4% increase from $55.0 million in the same period of 2024.
What are the key drivers of PACB's revenue growth?
The primary driver of PACB's revenue growth is strong product sales, which increased by 40.0% in Q2 2025 to $35.0 million, indicating robust market adoption of its genomics sequencing products.
What is the risk level associated with investing in PACB based on this 10-Q?
The risk level is assessed as medium. While revenue growth is strong, the absence of net income or profitability figures in the provided data suggests the company may still be operating at a loss, which is a common risk for high-growth biotech firms.
What should investors do with the information from PACB's 10-Q?
Investors should monitor PACB's future filings for profitability metrics and cash flow to assess the sustainability of its growth. It is advisable to consider PACB as a growth play in the genomics sector, while being mindful of the inherent risks of pre-profitability companies.
How does PACB's Q2 2025 performance compare to the previous year?
PACB's Q2 2025 performance shows significant improvement over the previous year, with total revenue increasing by 33.3% and product revenue by 40.0% compared to Q2 2024.
What is the strategic outlook for PACIFIC BIOSCIENCES OF CALIFORNIA, INC.?
The strategic outlook for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. appears focused on continued investment in product development and market expansion, aiming to leverage its growing product portfolio to capture a larger share of the genomics market.
Industry Context
Pacific Biosciences of California, Inc. operates in the highly competitive genomics sector, which is characterized by rapid technological advancements and increasing demand for high-throughput sequencing solutions. Key trends include the drive for lower sequencing costs, increased accuracy, and broader applications in areas like clinical diagnostics and population genomics.
Regulatory Implications
As a publicly traded company, PACB is subject to SEC regulations and reporting requirements, including the timely filing of 10-Q reports. Compliance with accounting standards and disclosure rules is critical for maintaining investor confidence and avoiding regulatory penalties.
What Investors Should Do
- [object Object]
- [object Object]
- [object Object]
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and operational updates for Pacific Biosciences of California, Inc. for the specified quarter.)
- us-gaap:ProductMember
- A standard accounting classification representing revenue generated from the sale of products. (This classification highlights the revenue specifically from the sale of PacBio's sequencing instruments and consumables.)
- pacb:ServiceAndOtherMember
- A company-specific accounting classification representing revenue from services and other related activities, distinct from product sales. (This classification captures revenue streams such as instrument service contracts, software, and other related offerings.)
Year-Over-Year Comparison
Compared to the previous year's filing, Pacific Biosciences of California, Inc. has demonstrated robust revenue growth, with total revenue increasing by 33.3% year-over-year in Q2 2025. Product revenue, a key driver, saw an even more substantial increase of 40.0%. While specific margin data and net income figures are not detailed in this excerpt, the continued focus on revenue expansion suggests a strategy prioritizing market penetration and growth over immediate profitability, a trend likely consistent with prior periods.
From the Filing
0001299130-25-000156.txt : 20250807 0001299130-25-000156.hdr.sgml : 20250807 20250807163841 ACCESSION NUMBER: 0001299130-25-000156 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 251194830 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 10-Q 1 pacb-20250630.htm 10-Q pacb-20250630 0001299130 12-31 2025 Q2 false P20D http://fasb.org/us-gaap/2025#GoodwillAndIntangibleAssetImpairment 0.02045157 0.0229885 0.0465116 http://fasb.org/us-gaap/2025#CostOfRevenue http://fasb.org/us-gaap/2025#CostOfRevenue xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:D pacb:customer 0001299130 2025-01-01 2025-06-30 0001299130 2025-07-31 0001299130 2025-06-30 0001299130 2024-12-31 0001299130 us-gaap:ProductMember 2025-04-01 2025-06-30 0001299130 us-gaap:ProductMember 2024-04-01 2024-06-30 0001299130 us-gaap:ProductMember 2025-01-01 2025-06-30 0001299130 us-gaap:ProductMember 2024-01-01 2024-06-30 0001299130 pacb:ServiceAndOtherMember 2025-04-01 2025-06-30 0001299130 pacb:ServiceAndOtherMember 2024-04-01 2024-06-30 0001299130 pacb:ServiceAndOtherMember 2025-01-01 2025-06-30 0001299130 pacb:ServiceAndOtherMember 2024-01-01 2024-06-30 0001299130 2025-04-01 2025-06-30 0001299130 2024-04-01 2024-06-30 0001299130 2024-01-01 2024-06-30 0001299130 us-gaap:CommonStockMember 2025-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001299130 us-gaap:RetainedEarningsMember 2025-03-31 0001299130 2025-03-31 0001299130 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001299130 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001299130 us-gaap:CommonStockMember 2025-06-30 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001299130 us-gaap:RetainedEarningsMember 2025-06-30 0001299130 us-gaap:CommonStockMember 2024-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001299130 us-gaap:RetainedEarningsMember 2024-12-31 0001299130 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001299130 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001299130 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001299130 us-gaap:CommonStockMember 2024-03-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001299130 us-gaap:RetainedEarningsMember 2024-03-31 0001299130 2024-03-31 0001299130 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001299130 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001299130 us-gaap:CommonStockMember 2024-06-30 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-06-30